Kura Oncology (KURA) Receivables (2024 - 2026)

Kura Oncology (KURA) has 3 years of Receivables data on file, last reported at $9.3 million in Q1 2026.

• Receivables for Q1 2026 came in at $9.3 million, down 80.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.3 million (down 80.82% YoY), and the FY2025 annual result was $8.8 million, up 327.38% from the prior year.
• Receivables climbed to $9.3 million in Q1 2026 per KURA's latest filing, from $8.8 million in the prior quarter.
• Over five years, Receivables peaked at $48.7 million in Q1 2025 and troughed at $2.1 million in Q4 2024.
• A 3-year average of $18.2 million and a median of $9.1 million in 2025 frame the typical range for Receivables.
• The sharpest annual moves came in 2025 and 2026: Receivables soared 327.38% in 2025, then plunged 80.82% in 2026.
• A 3-year view of Receivables shows it stood at $2.1 million in 2024, then soared by 327.38% to $8.8 million in 2025, then rose by 6.18% to $9.3 million in 2026.
• Business Quant data shows KURA's Receivables at $9.3 million in Q1 2026, $8.8 million in Q4 2025, and $35.9 million in Q3 2025.